Biosimilar Medicines Equal More Accessible Care for Patients

Tuesday June 28, 2022

Infographic describing how biosimilars save patients money and create new days of patient therapy.

Biosimilars are safe, effective, FDA-approved medicines used to treat diseases at lower costs than brand-name biologics. To date, biosimilars been used in more than 121 million days of patient therapy, and have also generated over 10 million additional days of therapy than if biosimilars weren’t available. This means  even more patients today are managing their diseases and focusing on living healthy lives thanks to biosimilar medicines.

View this infographic to see how biosimilars are helping patients every day, and why we need to continue fighting to expand patient access to them.

If you want to learn more about how biosimilars help patients have access to more-affordable care, read our blog here.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.